Recipharm is pleased to announce that the results of the study with Erdosteine as add-on treatment for COVID-19 patients are now available.

The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region most affected by SARS-CoV-2.

The study indicates that patients taking Erdosteine after hospital discharge benefits significant improvements in health-related quality of life parameters (HRQoL) and dyspnea. This study is one of the first to report HRQoL details in patients with COVID-19. Click here to access the publication.